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Type 1 IFN was first described over 50 yr ago 
as the factor responsible for the phenomenon 
of  viral  interference  (the  ability  of  infection 
with a virus to induce resistance to infection with 
a different virus; Isaacs and Lindenmann, 1957; 
Nagano and Kojima, 1958). Of all the mem-
bers of the type I IFN family of class II -helical 
cytokines in human and mice, IFN- (repre-
sented by several partially homologous genes) 
and IFN- (represented by a single gene) are 
the best characterized and most broadly ex-
pressed (Decker et al., 2005). Other type I IFN 
subtypes are less well characterized, may be more 
tissue restricted, and may not be represented in 
all the species. All type I IFN share a ubiqui-
tously expressed heterodimeric receptor com-
posed of two chains, IFNAR1 and IFNAR2, 
which signal through two Janus family kinases, 
Tyk2 and Jak1, resulting in recruitment of 
STAT1 to receptor-bound STAT2 and forma-
tion of STAT1-STAT2 heterodimers that dis-
sociate from the receptors and migrate into the 
nucleus (Li et al., 1996, 1997; Decker et al., 
2005).  In  the  nucleus,  STAT1-STAT2  het-
erodimers associate with the transcription fac-
tor IFN regulatory factor (IRF) 9 (p48) to form 
the heterotrimeric complex IFN-stimulated 
gene factor 3 (ISGF3), which binds to upstream 
sequence elements (IFN-stimulated response 
elements) and activates the transcription of 
IFN-inducible genes. IFNAR can also signal 
by inducing the activation and nuclear translo-
cation of STAT1 homodimers that bind to 
IFN-–activated sequences in the promoters of 
IFN-–induced genes (Decker et al., 2005).
A distinct category of type I–like IFN, also 
referred to as type III IFN, is the IFN- family, 
which  includes  IFN-1,  -2,  and  -3  (also 
called IL-28A, IL-28B, and IL-29). IFN-s bind 
to a receptor comprised of a specific ligand-
binding chain (IL-28R) and the IL-10R2 chain, 
which is shared by the IL-10 family of cyto-
kines (Uzé and Monneron, 2007). The IFN- 
receptors, like the IFNARs, activate the ISGF3 
complex, but unlike the IFNARs, they are re-
stricted in their tissue distribution, are not highly 
expressed in hematopoietic cells, and act pre-
dominantly at epithelial surfaces.
The type II IFN subtype is represented by a 
single gene product, IFN-, which binds to a 
distinct heterodimeric receptor formed by the 
two chains IFNGR1 and IFNGR2 that signal 
through Jak1 and Jak2 to phosphorylate STAT1 
homodimers (Young and Bream, 2007). STAT1 
homodimers then bind to IFN-–activated se-
quences in the promoters of IFN-–induced 
genes. The IFN- receptors are ubiquitous, 
but their expression on different cell types can 
be modulated.
Production of type I IFN
Type I IFNs can be produced by almost any 
cell type in the body in response to stimulation 
of an array of transmembrane and cytosolic re-
ceptors. In most cell types, the prevalent path-
way of type I IFN induction is the activation of 
cytosolic receptors that recognize viral or other 
xenogeneic or autologous nucleic acid, partic-
ularly double-stranded RNA (dsRNA; Kawai 
and Akira, 2010; Fig. 1). The RNA helicases 
retinoic acid–inducible gene I (RIG-I) and 
melanoma differentiation-associated gene 5 are 
the prevalent cytoplasmic receptors responsible 
for triggering type I IFN secretion. These re-
ceptors (RIG-I–like receptors) transmit signals 
through  the  mitochondria-localized  adaptor 
molecule  IPS-1  or  MAVS  and  the  kinases 
TBK1 and IKKi to activate IRF3 and induce 
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Although the role of type I interferon (IFN) in the protection against viral infections has 
been known and studied for decades, its role in other immunologically relevant scenarios, 
including bacterial infections, shock, autoimmunity, and cancer, is less well defined and 
potentially much more complicated.
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to TLR signaling.   
Thus, TRAF3 links 
TLR adaptors and 
downstream regula-
tory  kinases  important  for  IRF  activation  (Häcker  et  al., 
2006; Oganesyan et al., 2006).
Although all or most cell types can produce type I IFN, 
the existence of a cell type specialized for the production of 
large amounts of type I IFN and required for NK cell–mediated 
killing  of  virus-infected  cells  (natural  IFN-producing  cell) 
was identified in humans over 30 yr ago (Trinchieri et al., 
1978), and more recently was discovered in the mouse 
(Asselin-Paturel et al., 2001). Natural IFN-producing cells 
are now usually referred to as plasmacytoid DCs (pDCs) be-
cause of their round morphology, eccentric nucleus, and abun-
dant endoplasmic reticulum (Colonna et al., 2004). pDCs 
preferentially express the intracellular endosomal receptors 
TLR7 and TLR9, allowing them to respond to single-stranded 
RNA and DNA viruses, respectively, by triggering signal 
transduction through the adaptor protein MyD88 (Colonna 
et al., 2004). These receptors are efficient in inducing type I 
IFN only in pDCs because these cells constitutively express 
IRF7 (and IRF8), and the MyD88–IRF7 complex under-
goes a spatiotemporal regulation upon TLR ligation such 
that it is retained in the endosomal compartment, where it 
induces type I IFN production (Colonna et al., 2004). Bacte-
rial DNA can activate TLR9 in these cells, and it has recently 
been shown that phagosomal bacteria such as group B strep-
tococcus, but not cytosolic bacteria, also induce type I IFN in 
conventional DCs via TLR7, MyD88, and IRF1 (Mancuso 
et al., 2009). In many (but not all) viral infections, pDCs are 
important for the production of most early circulating type I 
transcription of the type I IFN genes (Kawai and Akira, 2010). 
A cytosolic DNA sensor, DNA-dependent activator of IRFs 
(DAI) or Z-DNA binding protein 1, was shown to induce 
type I IFN in response to the right-handed dsDNA conforma-
tion (B-DNA) in a TBK1- and IRF3-mediated mechanism 
(Kawai and Akira, 2010). However, DAI may not be a unique 
DNA sensor and may not be active on all cell types. The exis-
tence of other cytoplasmic DNA sensors is also suggested by 
the ability of the bacterial second messenger cyclic-di-GMP to 
potently induce type I IFN via a mechanism that is independent 
of DAI or other known cytoplasmic receptors but requires 
TBK1 and IRF3 (McWhirter et al., 2009). An alternative 
mechanism of dsDNA sensing depends on the ability of cyto-
solic DNA-dependent RNA-polymerase III to transcribe   
B-DNA into 5-ppp RNA, which then activates type I IFN 
transcription through RIG-I (Chiu et al., 2009).
The production of type I IFN is further regulated by a 
positive feedback loop that is based on the ability of IFN- 
and IFN-4 to induce the transcription of IRF7 and, at least 
in DCs, IRF8 (Marié et al., 1998; Tailor et al., 2007; Fig. 1). 
Once phosphorylated, these transcription factors help drive 
the expression of all genes of the type I IFN family, thereby 
amplifying type I IFN production.
In some cell types (e.g., macrophages and DCs), type I IFN 
is produced in response to triggering of the transmembrane 
receptors Toll-like receptor 3 (TLR3) and TLR4 by dsRNA 
and lipopolysaccharide, respectively (Fig. 1). TLR3 and TLR4 
signal through the adaptor molecule TRIF, which associates 
with TBK1 and activates IRF3 (Kawai and Akira, 2010). TNF   
receptor-associated factor 3 (TRAF3) associates with TRIF,   
as well as TBK1 and IKKi, and is required for production of   
type I IFN and IL-10, but not other cytokines, in the response 
Figure 1.  Mechanisms of type I IFN  
production. Type I IFN production can be trig-
gered by recognition of dsRNA by the cytosolic 
receptors MDA5 and RIG-I or of dsDNA  
(B-DNA) by DAI or as yet unknown cytosolic 
DNA receptors (DNA-RX), leading to activation 
of the IRF3 via the kinase TBK-1 (or IKKi)  
and culminating in production of type I IFN 
(IFN/4). dsDNA can also be transcribed by 
RNA-polymerase III into 5-pppRNA, which 
triggers RIG-I. The ability of the bacterial prod-
uct cyclic-di-GMP to induce type I IFN sug-
gests the existence of additional DNA sensors. 
The production of type I IFN can be amplified 
by a positive feedback loop in which the early 
produced IFN- and IFN-4 trigger the tran-
scription of IRF7 and, at least in DCs, IRF8.  
In macrophages and DCs, ligation of TLR3, TLR4, 
TLR7, and TLR9 triggers type I IFN production 
via signaling through adaptor molecules, in-
cluding MyD88, TIRAP, TRAM, and TRIF. TRIF 
associates with TBK1 to activate IRF3, whereas 
TLR7 and TLR9 signal through MyD88 and 
IRAK4 to activate IRF7. The cytoplasmic NOD 
receptors can also induce type I IFN produc-
tion in response to bacterial cell wall compo-
nents via activation of the kinase RICK and  
downstream signaling molecules including  
NF-B and TBK-1.JEM VOL. 207, September 27, 2010  2055
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of the genus Chlamydia replicating in nonhematopoietic   
human cells (de la Maza et al., 1985). In this case, rather than 
inducing intracellular killing of the bacteria, type I IFN in-
hibits the Chlamydia growth cycle at the point of transforma-
tion from elementary to reticulate body, resulting in chronic   
infection and failure to produce infectious organisms (Ishihara   
et al., 2005). The anti-Chlamydia effect of type I IFN is reversed 
by exogenous L-tryptophan and iron, which are essential for 
chlamydial growth, possibly secondary to induction of In-
doleamine 2,3-dioxygenase (Ishihara et al., 2005; Puccetti, 
2007). In human endothelial cells, MAVS, IRF3, IRF7, and 
endogenous IFN- are necessary for the control of C. pneu-
moniae replication (Buss et al., 2010). Similarly, the limited 
ability of Legionella pneumophila to replicate in murine mac-
rophages is caused by an effective innate response involving 
autocrine type I IFN signaling. In these cells, IFN suppresses 
intracellular replication of L. pneumophila via a STAT1-,   
2-, and 3-independent pathway that induces the differentia-
tion of classically activated macrophages as well as the pro-
duction of nitric oxide, which is required for the antibacterial 
effect (Plumlee et al., 2009). Type I IFN also protects mice 
against Salmonella typhimurium infection by activating IFN- 
production via STAT4 activation in an IL-12-independent 
way (Freudenberg et al., 2002). Phagosomal bacteria such   
as group B streptococci can induce type I IFN via TLR7,   
and this is important for production of proinflammatory   
cytokines by macrophages and resistance to the infection   
(Mancuso et al., 2007, 2009). Other possible antibacterial 
effects of type I IFN have been postulated based on its ability 
to modulate innate and adaptive response against bacteria,   
e.g., NK cell activation, antibody production, and DC acti-
vation (Decker et al., 2005).
Often, however, the production of type I IFN is associ-
ated with suppression of the innate response to the bacte-
rial infections. Indeed, type I IFN receptor–deficient mice 
(IFNAR/) are more resistant to infection with Francisella 
tularensis and Listeria monocytogenes than are WT mice (Fehr et al., 
1997; Auerbuch et al., 2004; Carrero et al., 2004; Stockinger 
and  Decker,  2008;  O’Connor  et  al.,  2009;  Henry  et  al., 
2010). Furthermore, the ability of Mycobacterium tuberculosis 
strains to induce type I IFN production has been proposed to 
correlate with bacterial virulence (Manca et al., 2001, 2005). 
M. tuberculosis–infected IFNAR/ mice have decreased and 
late mortality compared with WT animals (Manca et al., 
2005); however, at least in the first 2–3 mo after infection, 
their bacterial load was similar in the lungs and only slightly 
lower in the spleen (Cooper et al., 2000; Manca et al., 2005; 
Stanley et al., 2007). Modular and pathway analysis of the 
transcriptomes from the blood of patients with tuberculosis 
revealed that the signature was dominated by a neutrophil-
driven IFN-inducible gene profile, consistent with both type I 
and type II IFN signaling, suggesting both changes in cellular 
composition and altered gene expression (Berry et al., 2010).   
Thus, type I IFN has a hitherto underappreciated role in   
tuberculosis pathogenesis, which has implications for vaccine, 
diagnostic, and therapeutic development.
IFN, but are not essential for antiviral innate resistance, as 
many other cell types are able to produce type I IFN during 
the infection (Colonna et al., 2004).
A novel mechanism of type I IFN production by cyto-
plasmic ligands was shown to involve the nucleotide-binding 
oligomerization domain–containing protein (NOD) 1 and 
NOD2 receptors (Pandey et al., 2009; Watanabe et al., 2010). 
NODs are CARD-containing cytoplasmic molecules in epithe-
lial and hematopoietic cells that contain leucine-rich repeats 
recognizing related muropeptide subunits of the bacterial 
wall. NODs signal through the kinase Rip2 (also called RICK) 
and activate NF-B and other transcription factors, resulting 
in the production of proinflammatory cytokines. It has re-
cently been observed, however, that RICK can interact with 
TRAF3 and MAVS, thus inducing the activation of TBK1 
and IKKi, phosphorylation of IRF5 or IRF7, and transcrip-
tion of the IFN- gene (Fig. 1). Type I IFN can be induced 
by Mycobacterium tuberculosis through the activation of NOD2 
in macrophages (Pandey et al., 2009) and by Helicobacter pylori 
through NOD1 in epithelial cells (Watanabe et al., 2010).
Role of type I IFN in viral versus bacterial infections
Exposure of cells to IFN before infection induces an antiviral 
state that prevents productive viral infection. IFN receptor 
signaling induces and activates intrinsic antiviral factors such 
as RNA-activated protein kinase, the 2-5A system, and the 
Mx proteins. In addition, IFNs potently regulate both innate 
and adaptive immune responses, acting directly or indirectly 
on NK cells, T cells, B cells, DCs, and phagocytic cells (Prchal 
et al., 2009). In most or all pathogenic virus infections, early 
production of type I IFN is required to limit initial viral rep-
lication before effective humoral or cellular adaptive immune 
mechanisms become operational. Not surprisingly, many vi-
ruses have evolved molecular mechanisms to either prevent 
type I IFN induction or block the signaling through its re-
ceptors (Bowie and Unterholzner, 2008). However, in addi-
tion to their cell intrinsic or extrinsic antiviral effects, IFNs 
mediate many anticellular effects by modulating cell viability 
and function (e.g., induction of apoptosis, autophagy, differ-
entiation, cell migration, and inhibition of cell proliferation 
and angiogenesis; Bekisz et al., 2010; Mattei et al., 2010). 
Thus, IFN produced during viral infection, other pathologi-
cal conditions, or in the presence of DNA released by dying 
cells may mediate unwanted toxicity or induce pathological   
damage and inflammatory or autoimmune syndromes (Pascual 
et al., 2010). A typical example is the role of type I IFN in 
chronic HIV infection. HIV induces type I IFN, which   
together with tryptophan catabolism, may drive T cell dys-
function, and also contribute to other aspects of the disease 
pathogenesis (Boasso et al., 2008).
In bacterial infections, type I IFN is often produced, but its 
effects are complicated and do not always favor the immune 
response of the host against the infection. As in viral infections, 
IFNs sometimes participate in the resistance against bacterial 
infections. The first observation of the ability of type I IFN to 
prevent the intracellular replication of bacteria was for pathogens 2056 Type I interferon: friend or foe? | Trinchieri
F.  tularensis and L. monocytogenes infections (Henry et al., 
2010) and limits Th1 immune responses to M. tuberculosis in 
part by inducing negative regulator molecules such as sup-
pressor of cytokine signaling proteins (Manca et al., 2005). 
Type I IFN can also suppress Th17 responses by inducing the 
expression of IL-27, which then suppresses IL-17 production 
(Guo et al., 2008). Type I IFN also triggers the generation of 
IL-10–producing regulatory T (TR1) cells that dampen both 
innate and adaptive resistance to infection (Dikopoulos et al., 
2005; Levings et al., 2001).
Type 1 IFN might also affect antibacterial resistance by 
modifying the recruitment and activation of myeloid cells at 
the site of infection. Resistance to L. monocytogenes infection 
requires the CCL2- and CCL7-dependent recruitment of a 
class of activated monocytes/DCs that produces TNF and 
inducible nitric oxide synthase (Tip-DCs; Fig. 2) and medi-
ates innate immune defense (Jia et al., 2009). Signals through 
MyD88 are involved in the recruitment and activation of 
Tip-DCs, but these signals can be replaced in part by type I 
IFN. Thus, the deletion of IFNAR in MyD88-deficient mice 
results in increased rather than decreased susceptibility to in-
fection (Jia et al., 2009), indicating that type I IFN has both 
positive and negative effects on the resistance to L. monocyto-
genes infection.
The opposing roles of type I IFN are illustrated by influ-
enza virus and secondary bacterial infections (Fig. 2). Type I 
IFN is important for limiting influenza virus replication. 
However, IFN also induces chemokines such as CCL2 that 
recruit CCR2+ monocyte-derived DCs and macrophages 
to the site of infection, resulting in infection-associated pul-
monary pathology and mortality (Lin et al., 2008). On the 
other hand, type I IFN inhibits the production of CXCR2 
ligands, thus reducing neutrophil recruitment and facilitat-
ing  the  development  of  secondary  bacterial  pneumonia 
(Shahangian et al., 2009). A similar type I IFN–mediated 
decrease in neutrophil numbers was observed in mice in-
fected with lymphocytic choriomeningitis virus and was as-
sociated with susceptibility to bacterial infection (Navarini 
et al., 2006). In addition, IFN induced by intranasal poly-
IC treatment exacerbates tuberculosis in mice by recruit-
ing a population of CCR2-expressing macrophages that is 
highly permissive for M. tuberculosis proliferation (Antonelli 
et al., 2010).
Role of type I IFN in endotoxin shock
Type I IFN also has complex and often opposing effects in 
controlling susceptibility and lethality in various models of 
sepsis or endotoxic shock. During endotoxic shock in mice, 
type I IFN deficiency reduces LPS-induced lethality but not 
the production of other proinflammatory cytokines or nitric 
oxide (Karaghiosoff et al., 2003). Similar results were re-
ported in a model of high lethality septic peritonitis induced 
by colon ascendens stent, as well as in a model of liver in-
jury after ischemia and reperfusion (Weighardt et al., 2006; 
Zhai et al., 2008). In the septic peritonitis model, IFNAR/ 
mice displayed a significantly increased peritoneal neutrophil 
Several mechanisms may account for the deleterious ef-
fects of type I IFN in bacterial infections. Type I IFN increases 
the susceptibility of different cell types to apoptosis-inducing 
stimuli, in particular macrophages and lymphocytes. This is 
well described in infection with Listeria, Mycobacteria, Brucella, 
and Chlamydia spp (Carrero et al., 2004; Gold et al., 2004; 
O’Connell et al., 2004; Decker et al., 2005; Qiu et al., 2008).   
In L. monocytogenes infection, the pore-forming virulence   
factor  Listeriolysin  O  is  required  for  IFN  induction  in   
response to infection, and IFN in turn facilitates the Listeriolysin 
O–induced lysis of lymphocytes and macrophages (Carrero   
et al., 2004, 2006). Indeed, more virulent strains induce a higher 
level of type I IFN than do less virulent strains, and the dif-
ference in virulence disappears in IFNAR/ mice (Reutterer 
et al., 2008).
The mechanisms behind the proapoptotic effects of type I   
IFN are not fully known. Type I IFN alone is not sufficient 
to induce apoptosis in most cell types; rather, its effects likely 
involve up-regulation of caspases and pro-apoptotic innate 
sensors, such as TLRs and the inflammasomes. For example, 
production of type I IFN is required for Francisella spp to in-
duce inflammasome activation, possibly caused by the IFN-
driven up-regulation of the cytosolic AIM2 inflammasome 
(Choubey et al., 2010; Fernandes-Alnemri et al., 2010). Ac-
tivation of AIM2 then results in caspase1 activation and in the   
production of IL-1 and IL-18 as well as inflammasome-
  mediated cell death in infected cells. Type I IFN is also im-
portant to induce the up-regulation of RIG-I and melanoma 
differentiation-associated gene 5 in epithelial and other cells 
and this may represent a type I IFN amplifying loop in several 
types of infections (Haller et al., 2006; Jaitin and Schreiber, 
2007). These receptors respond to foreign nucleic acids and 
initiate a type I IFN-dependent proapoptotic signaling path-
way that requires the mitochondrial adapter IPS-1, induces 
the production of the proapoptotic BH3-only proteins Puma 
and Noxa, and culminates in the efficient activation of   
caspase-9-  and  Apaf-1-dependent  mitochondrial  apoptosis 
(Besch et al., 2009). Type I IFN is also required for the apop-
tosis resulting from infection-induced activation of the TRIF-
associated receptors TLR3 and TLR4, in part by suppressing 
Akt  signaling  and  degradation  of  the  CDK  inhibitor  p27 
(Hasan et al., 2007; Salaun et al., 2007).
Type I IFN may also interfere with intracellular bacteri-
cidal mechanisms. For example, type I IFN, may prevent the 
ability of IFN- to activate antibacterial function of macro-
phages either by directly interfering with IFN- signaling, as 
discussed or by lowering IFN- production. Type I IFN also 
exerts direct effects on phagocytic cells thus decreasing the 
activation of anti-microbial products and favoring bacterial 
replication and release (Rayamajhi et al., 2010). Thus, the 
evolutionary pressure for a rapid and strong innate resistance 
in the early stages of aggressive viral infections may have been 
stronger than that exerted by the relative decrease in resis-
tance to bacterial infections.
Type 1 IFN also directly affects T cell responses. It 
constrains the secretion of IL-17 by T cells, as observed in JEM VOL. 207, September 27, 2010  2057
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TNF induces IFN- production in vitro, 
and this may establish an autocrine loop that 
promotes the sustained production of che-
mokines and other STAT1-dependent genes 
(Yarilina et al., 2008).
Cross-regulation of type I and II IFNs
Although type I and type II IFN share some 
common mechanisms in the activation of 
the immune response, IFN- is generally a   
more potent activator of phagocytic cell and antigen-presenting 
cell function than type I IFN. The interaction between 
type I and type II IFN signals is complex and has received 
relatively little attention. Both types of IFN are often pro-
duced during the course of the same immune response, and 
evidence suggests that cross-regulation exerts physiologically 
meaningful effects (Fig. 3). For example, exposure of macro-
phages to type I IFN in vitro inhibits IFN- binding to the 
cells and prevents IFN- from enhancing class II MHC ex-
pression, Fc receptor expression, and oxidative burst (Ling 
et al., 1985; Yoshida et al., 1988). L. monocytogenes infection 
induces type I IFN production, which suppresses macrophage 
activation  by  IFN-  by  decreasing  IFNGR1  mRNA  and 
IFN- receptor surface expression (Rayamajhi et al., 2010).
In addition to signaling through the ISGF3 complex, type I 
IFN can activate STAT1 homodimers, and thus mimic the 
gene induction pattern of IFN- (van Boxel-Dezaire et al., 
2006). In addition, cells are continuously exposed to low lev-
els of type I IFN, and the resulting weak signal is required for 
the cells to produce high levels of IFN in response to induc-
ing stimuli (Taniguchi and Takaoka, 2001). For example, the 
priming of cells by constitutive sub-threshold type I IFN sig-
naling enhances their response to stimulation with other cyto-
kines, including an at least 10-fold enhancement of the response 
to IFN-, by favoring STAT1 activation. This sensitization 
has been attributed to the association of the two nonligand 
binding receptors components, IFNAR1 and IFNGR2, in 
the caveolar membrane domains (Takaoka et al., 2000).   
recruitment and activation, which is perplexing given that 
IFNAR/ mice had increased local production of CCL2, 
which primarily recruits macrophages, decreased CXCL10, 
which recruits NK cells and activated Th1 cells, and unal-
tered CXCL1, which recruits neutrophils (Weighardt et al., 
2006). However, despite their increased endotoxin resistance, 
IFNAR/ mice have increased late mortality in a low le-
thality model of cecal ligation and puncture (CLP)–induced 
sepsis (Fig. 2). Increased mortality in the CLP model was at-
tributed to decreased production of CXCL10 and failure to 
recruit the phagocytic neutrophils that are necessary for resis-
tance in this model (Kelly-Scumpia et al., 2010). The differ-
ential effect of type I IFN on neutrophil recruitment in the 
two models of polymicrobial sepsis is difficult to explain and 
might relate to differences in bacterial load and lethality. In 
influenza virus–infected mice, decreased neutrophil recruit-
ment to the lungs was attributed to the ability of type I   
IFN to decrease the production of CXCR2 ligands, such as   
CXCL1 and 2. This was not observed in either sepsis model, 
whereas CXCL10 production was decreased in both sepsis 
models, albeit with opposite effects on neutrophil recruit-
ment and activation (Weighardt et al., 2006; Shahangian et al., 
2009; Kelly-Scumpia et al., 2010). Clearly the role of type I 
IFN in chemokine-induced neutrophil recruitment falls short 
of explaining the full range of type I IFN’s regulatory effects 
on toxicity and infection in these complex models. A quite 
different mechanism should also be invoked to explain how 
type I IFN drives TNF-induced lethal shock (Huys et al., 2009). 
Figure 2.  Effects of type I IFN on chemokine 
production and leukocyte recruitment. Type I IFN 
drives the production of chemokines, such as CCL2 
and CCL7, which recruits CCR2-expressing TNF and 
inducible nitric oxide synthase–producing DCs  
(Tip-DCs) that are required for defense against Listeria 
infection. CCR2-expressing macrophages also con-
tribute to lung pathology during influenza infection 
and are highly permissive to infection with M. tuber-
culosis. During influenza infection, type I IFN inhibits 
the production of the CXCR2 ligands CXCL1 and 
CXCL2, thus decreasing neutrophil recruitment and 
dampening host defense against secondary bacterial 
infections. However, type I IFN also drives the pro-
duction of CXCL10, which recruits activated CXCR3-
expressing neutrophils, thus protecting against sepsis 
in response to CLP.2058 Type I interferon: friend or foe? | Trinchieri
mechanisms and the possible role of type I IFN in pathogen-
esis has remained difficult to determine (Münz et al., 2009; 
Rose, 2010). The development of Lyme arthritis after Borrelia 
burgdorferi infection is associated with an IFN-induced gene 
expression signature that is independent of T and B cells 
(Miller et al., 2008). Blocking type I, but not type II, IFN 
signaling reduced both the IFN signature and the develop-
ment of arthritis (Miller et al., 2008). Therapeutic treatment 
with type I IFN for cancer, chronic viral infections, and mul-
tiple sclerosis has been associated with significant collateral 
toxic effects characterized by chronic fatigue because of tran-
sient or chronic autoimmune pathology (Malik et al., 2001; 
Biggioggero et al., 2010). The mechanisms of type I IFN-
  induced autoimmunity has been attributed in part to increased 
DC activation and antigen uptake and presentation from apop-
totic cells, as well as increased production of autoantibodies 
(Jego et al., 2003; Rizza et al., 2010).
A  prominent  feature  of  systemic  lupus  erythematosus 
(SLE) is the increased expression of type I IFN–regulated genes 
in blood cells, which is often associated with the presence of 
IFN in the plasma (Bennett et al., 2003; Rönnblom and Alm, 
2003). The cells producing type I IFN in SLE appear to be 
predominantly pDC, which are reduced in number in the 
blood but are abundant in skin and lymph nodes (Rönnblom 
et al., 2009). In SLE patients, immune complexes consisting 
More recently, constitutive expression of c-Jun was shown to 
induce endocrine or paracrine production of low levels of 
IFN- that maintains expression of STAT1 required for optimal 
cellular responses to type I IFN, as well as to IFN- and IL-6   
(Gough et al., 2010). Furthermore, the induction of low levels of   
type I IFN during stimulation of DCs through innate receptors 
is essential for optimal production of the IL-12 p70 heterodi-
mer (Gautier et al., 2005), thus indirectly contributing to IFN- 
production. In the presence of high concentrations of type I 
IFN, however, the production of IL-12p40 is suppressed, lim-
iting the amount of IL-12 heterodimer (Byrnes et al., 2001).
By signaling through STAT4, type I IFN has also been 
reported to directly induce the production of IFN- in NK 
and T cells, particularly in the absence of STAT1, which nor-
mally suppresses IFN- production (Brinkmann et al., 1993; 
Freudenberg et al., 2002; Nguyen et al., 2000). Because of 
the transient nature of STAT4 activation by type I IFN and 
the regulatory effect of STAT1, the physiological role of type I 
IFN  in  controlling  IFN-  production,  as  compared  with 
classical IFN-–inducing cytokines such as IL-2 and IL-12, 
remains to be evaluated.
Type I IFN and autoimmunity
The connection between viral or other infections and auto-
immunity has been known for a long time, although the precise 
Figure 3.  Cross-talk between type I IFN and IFN-. High levels of type I IFN (solid arrows) decrease the expression of IFNGR1 and inhibit IFN--
induced activation of MHC class II expression, oxidative burst, and bactericidal activity in macrophages. However, low constitutive levels of type I IFN 
(dashed arrows) prime cells for secondary responses to type I and II IFNs and IL-6 by favoring expression and activation of STAT1 (shown in fibroblasts).  
In DCs, low concentrations of type I IFN are essential for the optimal production of the IFN-–inducing cytokine IL-12p70, whereas higher levels of type I 
IFN suppress TLR- and IFN-–induced IL-12p40 expression, thus dampening IL-12p70 production. Type I IFN can also directly induce the production of 
IFN- in NK cell and T cells via the activation of STAT4.JEM VOL. 207, September 27, 2010  2059
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are most likely linked to its immunoregulatory effects, includ-
ing its ability to affect IL-12 production, to activate regula-
tory T cells, and to constrain Th17 cell–mediated autoimmune 
inflammation (Byrnes et al., 2001; Levings et al., 2001; 
Dikopoulos et al., 2005; Guo et al., 2008).
Type I IFN and cancer
Several of the biological functions of type I IFN, including its 
regulation of innate and adaptive immunity and its antiangio-
genic and proapoptotic effects, make it an obvious candidate 
for anti-cancer therapy. Indeed, type I IFN has been used 
with some success for the treatment of several types of cancer, 
including hematological malignancies (hairy cell leukemia, 
chronic myeloid leukemia, and some B and T cell lymphomas), 
and solid tumors (melanoma, renal carcinoma, and Kaposi’s sar-
coma; Ferrantini et al., 2007; Moschos and Kirkwood, 2007). 
In some of those indications, type I IFN therapy is still in use; 
in others it has been superseded by more effective targeted 
therapies. The antitumor effect of type I IFN therapy is accom-
panied by severe side effects, including autoimmune and in-
flammatory symptoms, as well as direct tissue toxicity, that are 
probably responsible for the hematological and neurological   
side effects. It was recently shown that endogenous type I   
IFN, like IFN-, prevents the growth of primary carcinogen- 
induced and transplantable tumors (Dunn et al., 2005). Unex-
pectedly, unlike IFN-, type I IFN does not act directly on 
tumor cells. Hematopoietic cells, in particular NK cells, are 
critical IFN-/ targets during development of protective an-
titumor responses (Dunn et al., 2005; Swann et al., 2007). Thus, 
one of the earliest described immunoregulatory functions of 
type I IFN—its ability to regulate NK cell functions (Trinchieri 
and Santoli, 1978)—has now been proven to be one of the ma-
jor mechanisms of the regulation of tumor growth by endoge-
nous type I IFN. However, a possible intrinsic role of type I 
IFN in regulating tumor cell proliferation, apoptosis, and au-
tophagy, as discussed above for infectious diseases, should not 
be discounted and has only recently begun to be investigated in 
depth (Goldszmid et al., 2009). The ability of oncogenes such 
as Ras and HPV16 E6E7 to down-regulate IFN-inducing in-
nate receptors, RIG-I and TLR9, respectively, is suggestive of 
a role of type I IFN in modulating not only the infectiveness of 
oncogenic viruses but also their cell transforming ability (Hasan 
et al., 2007; Shmulevitz et al., 2010).
Conclusions
In these last few years, our understanding of the mechanisms 
controlling the production and the function of type I IFN in 
infection, immunity, autoimmunity, and oncology has been 
progressing at a very fast pace, and the role of this family of 
cytokines in physiology and pathology is finally starting to be 
fully appreciated. Type I IFN are essential for organisms to 
survive acute viral infection, even if many viruses have devel-
oped mechanisms to escape their effects. However, the or-
ganism pays a price for this effective innate resistance, as the 
toxicity of IFN causes acute and chronic morbidity and alters in-
nate and adaptive defenses against other opportunistic infections. 
of autoantibodies bound to self-DNA and RNA can stimulate 
production of type I IFN through TLR7 and TLR9 after being 
internalized following binding to Fc receptors (Rönnblom 
et al., 2009). Stimulation of pDCs through TLR7 and TLR9 
also renders these cells resistant to the apoptotic effect of glu-
cocorticosteroids, thus decreasing the ability of these drugs to 
reduce type I IFN production and effectively treat the pa-
tients (Guiducci et al., 2010). Several genes that have been 
associated with susceptibility to SLE are involved either in 
the regulation of the IFN response or in the ability to clear 
immune complexes through Fc receptors, and thus to degrade 
nucleic acid released from dying cells (Morel, 2010). The 
pathogenic role of type I IFN in SLE is mediated in part by 
its ability to induce immune activation, including a positive 
feedback loop that induces plasma cell maturation and increases 
autoantibody formation (Jego et al., 2003). Pathology in SLE 
could also be caused by the ability of type I IFN to directly 
induce pathogenic effects at the tissue level. For example, 
type I IFN directly induces vasculogenesis and may be re-
sponsible for the premature atherosclerosis found in SLE pa-
tients (Denny et al., 2007). The role of type I IFN in this 
disease has now been confirmed in lupus-prone mouse strains 
(Agrawal et al., 2009; Triantafyllopoulou et al., 2010).
The presence of pDCs in autoimmune target tissues is as-
sociated with an IFN-induced gene signature, suggesting the 
possible involvement of type I IFN in several other auto-
immune disorders, including diabetes mellitus, dermatomyositis, 
and Sjogren’s syndrome (Guiducci et al., 2009). A clear asso-
ciation also exists between type I IFN and cutaneous skin dis-
eases characterized by interface dermatitis, such as lichen planus, 
dermatomyositis, lichen sclerosus, cutaneous lupus, and cuta-
neous graft-versus-host disease, in which pDC infiltrates and 
deposition of nucleic acid–containing immune complexes is 
observed (Wenzel and Tüting, 2008). A pDC infiltrate linked 
to an IFN signature is also observed in psoriasis. Although 
tissue deposition of immune complexes is not observed in 
psoriasis, the antimicrobial cationic peptide LL-37 accumulates 
in lesions where it binds to and transports self-DNA and 
RNA to the early endosomal compartment of pDC, thereby 
stimulating type I IFN production through TLR9 and TLR7, 
respectively (Ganguly et al., 2009).
The involvement of type I IFN in the pathogenesis of 
several autoimmune diseases indicates the possibility to thera-
peutically target either type I IFN or the mechanisms leading 
to IFN production in those diseases (Guiducci et al., 2009; 
Pascual et al., 2010). Paradoxically, however, in several ex-
perimental and clinical autoimmune conditions, treatment 
with type I IFN or its induction has proven beneficial. In most 
cases, these conditions are tissue-specific autoimmune or in-
flammatory syndromes characterized by activation of effector 
Th1  and  Th17  responses,  including  arthritis,  inflammatory 
bowel diseases, and multiple sclerosis (Lee et al., 2006; Yarilina 
et al., 2007; Prinz et al., 2008). IFN- is a common and ef-
fective treatment for reducing disease recurrence in multiple 
sclerosis (Noseworthy et al., 2000; Comi, 2009). The mecha-
nisms by which type I IFN affects these pathological conditions 2060 Type I interferon: friend or foe? | Trinchieri
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This fact was recognized very early, as Dr. Louis Cruveilhier 
wrote during the Spanish flu epidemic of 1918–1919: “Si la 
grippe tue, c’est parce qu’elle frappe au thorax” or (to para-
phrase), “Flu condemns, and additional infection executes” 
(Cruveilhier, 1919). However, as the mechanisms underlying 
the actions of type I IFN are becoming better understood, 
there is hope of a more rationale therapeutic targeting.
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